Rivaroxaban is an oral anticoagulant drug, pivotal in treating thromboembolic diseases by selectively inhibiting Factor Xa. Approved in 2011 in the US, it effectively prevents conditions such as deep vein thrombosis, venous thromboembolism, and pulmonary embolism. By targeting FXa, it reduces thrombin generation, thus, interrupting blood coagulation pathways. While it offers significant therapeutic benefits, users may experience side effects ranging from fatigue to serious allergic reactions.